Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia (original) (raw)

References

  1. Blaeschke F, Kaeuferle T, Feucht J, Weber D, Lotfi R, Kaiser A, Assenmacher M, Doering M, Feuchtinger T (2016) Defined central memory and stem memory T cell phenotype of CD4 and CD8 CAR T cells for the treatment of CD19+ acute lymphoblastic leukemia in an automated closed system. In: 58th ASH annual meeting and exposition. Blood, 128(22) (Abstract 4558)
  2. Stenger D, Blaeschke F, Kaeuferle T, Willier S, Lotfi R, Kaiser A, Assenmacher M, Doering M, Feucht J, Feuchtinger T (2017) Automated generation of central memory and stem cell-like memory CD19-specific CAR T cells in a closed, GMP compatible system. In: Cellular therapy, international symposium Erlangen, Erlangen (Abstract 134)
  3. Blaeschke F, Stenger D, Kaeuferle T, Willier S, Lotfi R, Kaiser A, Assenmacher M, Doering M, Feucht J, Feuchtinger T (2017) CD19-specific CAR T cells with a central memory and stem memory phenotype—automated generation in a closed, GMP-compatible system from peripheral blood of pediatric patients with acute lymphoblastic leukemia. In: 43rd annual meeting of the European Society for Blood and Marrow Transplantation (EBMT), Marseille (Abstract)
  4. Blaeschke F, Stenger D, Kaeuferle T, Willier S, Lotfi R, Kaiser A, Assenmacher M, Doering M, Feucht J, Feuchtinger T (2017) Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated GMP system for the treatment of CD19+ acute lymphoblastic leukemia. In: Annual meeting of Paediatrische Arbeitsgemeinschaft fuer Stammzelltransplantation and Zelltherapie (PAS&ZT), Hamburg (Abstract)
  5. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385(9967):517–528. https://doi.org/10.1016/S0140-6736(14)61403-3
    Article PubMed CAS Google Scholar
  6. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371(16):1507–1517. https://doi.org/10.1056/NEJMoa1407222
    Article PubMed PubMed Central CAS Google Scholar
  7. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33(6):540–549. https://doi.org/10.1200/JCO.2014.56.2025
    Article PubMed CAS Google Scholar
  8. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365(8):725–733. https://doi.org/10.1056/NEJMoa1103849
    Article PubMed PubMed Central CAS Google Scholar
  9. Orlowski RJ, Porter DL, Frey NV (2017) The promise of chimeric antigen receptor T cells (CARTs) in leukaemia. Br J Haematol 177(1):13–26. https://doi.org/10.1111/bjh.14475
    Article PubMed Google Scholar
  10. Maude S, Barrett DM (2016) Current status of chimeric antigen receptor therapy for haematological malignancies. Br J Haematol 172(1):11–22. https://doi.org/10.1111/bjh.13792
    Article PubMed CAS Google Scholar
  11. Sadelain M, Brentjens R, Riviere I (2013) The basic principles of chimeric antigen receptor design. Cancer Discov 3(4):388–398. https://doi.org/10.1158/2159-8290.CD-12-0548
    Article PubMed PubMed Central CAS Google Scholar
  12. Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, Maude SL, Raman P, Barrera A, Gill S, Lacey SF, Melenhorst JJ, Allman D, Jacoby E, Fry T, Mackall C, Barash Y, Lynch KW, Maris JM, Grupp SA, Thomas-Tikhonenko A (2015) Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 5(12):1282–1295. https://doi.org/10.1158/2159-8290.CD-15-1020
    Article PubMed PubMed Central CAS Google Scholar
  13. Jacoby E, Nguyen SM, Fountaine TJ, Welp K, Gryder B, Qin H, Yang Y, Chien CD, Seif AE, Lei H, Song YK, Khan J, Lee DW, Mackall CL, Gardner RA, Jensen MC, Shern JF, Fry TJ (2016) CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun 7:12320. https://doi.org/10.1038/ncomms12320
    Article PubMed PubMed Central CAS Google Scholar
  14. Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, Norris AP, Wong CW, Urak RZ, Chang WC, Khaled SK, Siddiqi T, Budde LE, Xu J, Chang B, Gidwaney N, Thomas SH, Cooper LJ, Riddell SR, Brown CE, Jensen MC, Forman SJ (2016) Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood 127(24):2980–2990. https://doi.org/10.1182/blood-2015-12-686725
    Article PubMed PubMed Central CAS Google Scholar
  15. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, Wang E, Douek DC, Price DA, June CH, Marincola FM, Roederer M, Restifo NP (2011) A human memory T cell subset with stem cell-like properties. Nat Med 17(10):1290–1297. https://doi.org/10.1038/nm.2446
    Article PubMed PubMed Central CAS Google Scholar
  16. Biasco L, Scala S, Basso Ricci L, Dionisio F, Baricordi C, Calabria A, Giannelli S, Cieri N, Barzaghi F, Pajno R, Al-Mousa H, Scarselli A, Cancrini C, Bordignon C, Roncarolo MG, Montini E, Bonini C, Aiuti A (2015) In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells. Sci Transl Med 7(273):273ra213. https://doi.org/10.1126/scitranslmed.3010314
    Article CAS Google Scholar
  17. Feucht J, Kayser S, Gorodezki D, Hamieh M, Doring M, Blaeschke F, Schlegel P, Bosmuller H, Quintanilla-Fend L, Ebinger M, Lang P, Handgretinger R, Feuchtinger T (2016) T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget 7(47):76902–76919. https://doi.org/10.18632/oncotarget.12357
    Article PubMed PubMed Central Google Scholar
  18. Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS (2016) Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Investig 126(8):3130–3144. https://doi.org/10.1172/JCI83092
    Article PubMed PubMed Central Google Scholar
  19. Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, Yeh R, Capacio V, Olszewska M, Hosey J, Sadelain M, Brentjens RJ, Riviere I (2009) Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother 32(2):169–180. https://doi.org/10.1097/CJI.0b013e318194a6e8
    Article PubMed PubMed Central CAS Google Scholar
  20. Mock U, Nickolay L, Philip B, Cheung GW, Zhan H, Johnston IC, Kaiser AD, Peggs K, Pule M, Thrasher AJ, Qasim W (2016) Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. Cytotherapy 18(8):1002–1011. https://doi.org/10.1016/j.jcyt.2016.05.009
    Article PubMed CAS Google Scholar
  21. Schneider D, Xiong Y, Wu D, Nlle V, Schmitz S, Haso W, Kaiser A, Dropulic B, Orentas RJ (2017) A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. J Immunother Cancer 5:42. https://doi.org/10.1186/s40425-017-0246-1
    Article PubMed PubMed Central Google Scholar
  22. Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, Hoglund V, Lindgren C, Oron AP, Li D, Riddell SR, Park JR, Jensen MC (2017) Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129(25):3322–3331. https://doi.org/10.1182/blood-2017-02-769208
    Article PubMed PubMed Central CAS Google Scholar
  23. Lock D, Mockel-Tenbrinck N, Drechsel K, Barth C, Mauer D, Schaser T, Kolbe C, Al Rawashdeh W, Brauner J, Hardt O, Pflug N, Holtick U, Borchmann P, Assenmacher M, Kaiser A (2017) Automated manufacturing of potent CD20-directed chimeric antigen receptor T cells for clinical use. Hum Gene Ther 28(10):914–925. https://doi.org/10.1089/hum.2017.111
    Article PubMed CAS Google Scholar
  24. Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M, Benedicenti F, Sergi LS, Ambrosi A, Ponzoni M, Doglioni C, Di Serio C, von Kalle C, Naldini L (2009) The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Investig 119(4):964–975. https://doi.org/10.1172/JCI37630
    Article PubMed PubMed Central CAS Google Scholar
  25. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG (2016) CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Investig 126(6):2123–2138. https://doi.org/10.1172/JCI85309
    Article PubMed PubMed Central Google Scholar
  26. Barrett DM, Singh N, Hofmann TJ, Gershenson Z, Grupp SA (2016) Interleukin 6 is not made by chimeric antigen receptor T cells and does not impact their function. In: 58th ASH annual meeting and exposition. Blood, 128(22) (Abstract 654)

Download references